Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer

SIMPLE SUMMARY: Immune checkpoint inhibitors have become the standard of care therapy in a multimodal setting for recurrent/metastatic HNSCC. Multiple clinical trials have recently looked at the addition of ICI to multimodal treatments in locally advanced HNSCC. Multiple Phase II/III trials are inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Yuan James, Goodman, Joseph F., Haroun, Faysal, Bauman, Julie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913370/
https://www.ncbi.nlm.nih.gov/pubmed/36765627
http://dx.doi.org/10.3390/cancers15030672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913370/
https://www.ncbi.nlm.nih.gov/pubmed/36765627
http://dx.doi.org/10.3390/cancers15030672

Ejemplares similares